Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jana Rulcová"'
Publikováno v:
Leukemia Research. 31:483-491
We compared the effect of control genes (CG): total Abelson (total-ABL), beta-2-microglobulin (B2M) and beta-glucuronidase (GUS), recommended in the Europe Against Cancer (EAC) program, on real-time BCR-ABL monitoring in patients with chronic myeloid
Publikováno v:
Leukemia Research. 33:582-584
Autor:
Katerina Machova Polakova, Václava Zmeková, Hana Klamova, Zuzana Zemanova, Jana Moravcová, Jana Rulcová
Publikováno v:
Leukemia & Lymphoma. 49:1620-1622
Publikováno v:
Leukemia research. 35(7)
Autor:
Daniela Žáčková, Vaclava Polivkova, Tomáš Jurček, Kateřina Machová Poláková, Zdeněk Pospíšil, Jana Rulcová, Jana Moravcová, Jiří Mayer, Hana Klamova, Dana Dvořáková
Publikováno v:
Experimental hematology. 38(1)
Objective Of 140 chronic myeloid leukemia patients responding to imatinib with complete cytogenetic remission, 32 exhibited a plateau of BCR-ABL values at ≥0.1% level in a minimum of three subsequent samples (minimal duration, 6 − 9 months). Medi
Publikováno v:
Leukemia Research. 29:1365-1366
Autor:
Zdenek Pospisil, Katerina Machova Polakova, Dana Dvorakova, Daniela Zackova, Hana Klamova, Jana Rulcová, Jana Moravcová, Tomáš Jurček, Jiri Mayer, Vaclava Polivkova
Publikováno v:
Blood. 114:2216-2216
Abstract 2216 Poster Board II-193 Introduction. The major cause of the imatinib resistance is the presence of point mutations within the ABL kinase domain of BCR-ABL that are occurred in approximately 35-70% of patients displaying resistance to imati